Donna Stock-Novack

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

David S. Alberts, S Green, Edward V. Hannigan et al. · Journal of Clinical Oncology · 1992 · 299 citations

Medicine, Oncology, Pharmacology +16

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

BG Durie, Donna Stock-Novack, SE Salmon et al. · Blood · 1990 · 163 citations · Full text

Medicine, Hematology, Oncology +9

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

BG Durie, Donna Stock-Novack, SE Salmon et al. · Blood · 1990 · 147 citations

Medicine, Hematology, Oncology +9

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

David S. Alberts, Richard A. Kronmal, Lawrence Baker et al. · Journal of Clinical Oncology · 1987 · 80 citations

Medicine, Oncology, Pharmacology +14

Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A southwest oncology group study

David S. Alberts, Steve Dahlberg, Stephanie Green et al. · Cancer · 2010 · 74 citations

Medicine, Gynecology, Oncology +16